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ABSTRACT
OBJECTIVE
To determine whether treatment of isolated stable 
Weber B type ankle fractures with a cast or a simple 
orthotic device for three weeks produces non-inferior 
outcomes compared with conventional immobilisation 
in a cast for six weeks.
DESIGN
Randomised, pragmatic, non-inferiority, clinical trial 
with blinded outcome assessment.
SETTING
Two major trauma centres in Finland, 22 December 
2012 to 6 June 2016.
PARTICIPANTS
247 skeletally mature patients aged 16 years or older 
with an isolated Weber B type fibula fracture and 
congruent ankle mortise in static ankle radiographs.
INTERVENTIONS
Participants were randomly allocated to conventional 
six week cast immobilisation (n=84) or three week 
treatment either in a cast (n=83) or in a simple 
orthosis (n=80).
MAIN OUTCOME MEASURES
The primary, non-inferiority, intention-to-treat 
outcome was the Olerud-Molander Ankle Score 
at 12 months (OMAS; range 0-100; higher scores 
indicate better outcomes and fewer symptoms). The 
predefined non-inferiority margin for the primary 
outcome was −8.8 points. Secondary outcomes were 
ankle function, pain, quality of life, ankle motion, and 
radiographic outcome. Follow-up assessments were 
performed at 6, 12, and 52 weeks.
RESULTS
212 of 247 randomised participants (86%) completed 
the study. At 52 weeks, the mean OMAS was 87.6 (SD 
18.3) in the six week cast group, 91.7 (SD 12.9) in the 
three week cast group, and 89.8 (SD 18.4) in the three 
week orthosis group. The between group difference 
at 52 weeks for the three week cast versus six week 
cast was 3.6 points (95% confidence interval −1.9 to 
9.1, P=0.20), and for the three week orthosis versus 
six week cast was 1.7 points (−4.0 to 7.3, P=0.56). 
In both comparisons, the confidence intervals did 
not include the predefined inferiority margin of −8.8 
points. The only statistically significant between group 
differences observed in the secondary outcomes and 
harms in the two primary comparisons were slight 
improvement in ankle plantar flexion and incidence of 
deep vein thrombosis, both in the three week orthosis 
group versus six week cast group.
CONCLUSION
Immobilisation for three weeks with a cast or orthosis 
was non-inferior to conventional cast immobilisation 
for six weeks in the treatment of an isolated stable 




Ankle fracture is a common injury, with an annual 
incidence between 122 and 187 per 100 000 
population.1-3 Seventy per cent of ankle fractures are 
unimalleolar injuries and the Weber B type fibula 
fracture is by far the most common type of ankle 
fracture.1 3-8 These fractures can be either stable 
or unstable depending on the accompanying soft 
tissue injury.6-16 The stability of the ankle mortise 
has fundamental clinical relevance, as it dictates the 
treatment strategy.6-16 Stable ankle fractures can be 
treated non-surgically7 8 16-20 and account for about 
half of ankle fractures.13
It is recognised that it takes approximately six weeks 
to achieve sufficient fracture healing (bone union) to 
resist strains caused by weightbearing. In keeping with 
this belief, the traditional non-operative treatment of a 
stable Weber B type fracture is a below-the-knee cast 
for six weeks.8 16-22 Abundant evidence confirms that 
this strategy leads to a high rate of fracture union,16-22 
but it is associated with harms, such as increased ankle 
stiffness and deep vein thrombosis.21 23-26 Awareness of 
this trade-off between benefits and harms has been a 
catalyst towards considering shorter, more functional 
and less bothersome non-operative strategies that 
would still result in successful fracture healing.24 25 27-30
Evidence from biomechanical studies suggests 
that an early mechanical stimulus is a critical factor 
in the healing of stable fractures, warranting further 
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investigation of clinical response to shorter durations 
of immobilisation.31-33 A few small patient series 
have shown that isolated stable fibula fractures can 
be treated successfully even without sturdy external 
ankle support.27-29 34 On the basis of these findings we 
tested whether isolated fibular fractures identified as 
stable using an external rotation stress test11 could be 
treated by immobilisation for only three weeks—even 
using an orthosis that merely provides patients with 
some psychological support and comfort to enable 
immediate weightbearing.
We conducted a pragmatic, multicentre, randomised, 
non-inferiority trial to compare the conventional 
strategy of immobilisation using a cast for six weeks 
with immobilisation for three weeks (using either a cast 
or an orthosis) for isolated stable Weber B type fibular 
fractures. We hypothesised that successful fracture 
healing of such fractures can be achieved safely after 
only three weeks of immobilisation.
Methods
Trial design
We conducted a randomised, parallel group, non-
inferiority study to compare traditional immobilisation 
by cast for six weeks with immobilisation for three 
weeks using either a cast or an orthosis for isolated 
stable Weber B type ankle fractures at two trauma 
centres in Finland. The reporting of this study follows 
the CONSORT guidelines for non-inferiority trials.35 
Supplementary appendix 1 shows the study protocol 
and statistical analysis plan. No changes were made 
to the study protocol after the trial started. All patients 
gave written informed consent.
Participants
All skeletally mature patients (16 years or older) with 
an isolated Weber B type fibular fracture (fig 1) and 
congruent ankle mortise (medial clear space <4 mm 
and ≤1 mm wider than the superior clear space) in the 
primary radiographs (see supplementary appendix 1 
figure S1) visiting the emergency departments of either 
of the two participating university hospitals, were 
assessed for study eligibility. To assess the stability of 
the fracture, the orthopaedic surgeon on-call carried 
out an external rotation stress test11 under fluoroscopy 
(see supplementary appendix 1 figure S2). The fracture 
was considered stable when the medial clear space 
was less than 5 mm under external rotation stress, 
as measured between the lateral border of the medial 
malleolus and the medial border of the talus at the level 
of the talar dome11-13 (see supplementary appendix 
1 figure S2). Radiographs were calibrated using a 30 
mm disk, with measurements made to an accuracy of 
1 mm. Other inclusion criteria were the ability to walk 
unaided before the current trauma and enrolment 
fewer than seven days after the injury. We excluded 
patients with previous ankle fracture or suspicion 
of a previous deltoid ligament injury (a history of 
ankle twisting injury requiring cast treatment), other 
important fracture in the affected ankle or foot area, 
current bilateral ankle fracture, concomitant tibial 
fracture, pathological fracture, diabetic or other 
neuropathy, inadequate cooperation, or permanent 
residence outside the catchment area of the two study 
hospitals.
Randomisation and blinding
Patients were randomly allocated (1:1:1 ratio) to the 
six week cast, three week cast, or three week orthosis 
group using sealed and consecutively numbered, 
opaque envelopes. A biostatistician who was not 
involved in the clinical care of the patients prepared 
the envelopes using a computerised random number 
generator. Allocation was stratified by site and blocked 
within stratums using random permuted blocks 
(block size 6, 9, and 12). After consent had been 
obtained, the orthopaedic surgeon on-call individually 
randomised participants by opening the next available 
numbered envelope. These surgeons were not involved 
in further treatment of the participants. Blinding of 
participants was not possible because of the nature 
of the interventions. The unblinded participants self 
reported the primary outcomes, but the outcome 
assessors (trained study physiotherapists) of other 
study outcomes and doctors carrying out the follow-up 
visits were blinded to group allocation when possible.
Interventions
According to treatment group assignment, a trained 
plaster technician applied a standard below-the-knee 
cast (3M Scotchcast; St Paul, MN) for the three week 
or six week cast groups, or a commercially available, 
Randomised controlled trial
Skeletally mature patients with an isolated, stable Weber B type 
fibula fracture
247 Age: – years Multicentre trial% male
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simple orthotic device (Dynacast/Ortho-Glass; BSN 
medical, Rutherford College, NC) for the three week 
orthosis group, to ensure correct fit and comfort. The 
cast was applied from the tuberosity of the tibia to 
the base of the toes and was lined and padded (see 
supplementary appendix 1 figure S5). The orthotic 
device was applied according to the manufacturers’ 
instructions, from the middle third of the tibia to the 
calcaneus (see supplementary appendix 1 figures S3 
and S4).
Participants received guidance from a physiotherapist 
on walking with crutches. Weightbearing was permitted 
in all three groups immediately after the application of 
the cast or orthosis. Participants received written and 
verbal instructions on to how to cope with the ankle 
fracture and support (cast and orthosis groups) and how 
to remove and reapply the support (orthosis group). 
Although we did not perform a formal registration of 
problems related to ill fitting supports, or compliance 
with the external supports (cast or orthosis), we asked 
participants with such issues to contact the study 
hospitals. If problems were encountered, a new cast 
was applied. Participants in the three week orthosis 
group were instructed to wear the brace as necessary or 
according to comfort. They could take off the orthosis 
when needed and move their ankle freely. The cast or 
orthotic device was removed at the three week follow-
up visit. Those in the three week treatment groups 
(both orthosis or cast) were instructed to continue 
weightbearing as tolerated with no need for further 
bracing or support, whereas participants in the six 
week cast group received a new, below-the-knee cast.
Outcome measures
The primary outcome measure was the Olerud-Molander 
Ankle Score (OMAS; scale 0-100, with higher scores 
indicating better outcomes and fewer symptoms), a 
validated, condition specific, patient reported measure 
of ankle fracture symptoms.36 37 OMAS is an ordinal 
scale, but with 21 classes (scale 0-100, at intervals 
of 5 points), it is close to numerical continuum and is 
handled as such in the statistical analysis. The primary 
time point was 52 weeks, as predefined in the trial 
registration. The primary outcome was also assessed 
at six and 12 weeks, but these data were only intended 
to illustrate the trajectory of the treatment responses.
The secondary outcome measures were the Foot 
and Ankle Outcome Score (FAOS, five subscales from 
0-100, with higher scores indicating better function),38 
a 100 mm visual analogue scale for function and pain 
(range 0-100, with higher scores indicating more 
severe pain or dysfunction),39 the RAND 36-item health 
survey for health related quality of life (RAND-36, eight 
subscales from 0-100, with higher scores indicating 
better quality of life),40 range of motion (ROM) of the 
injured ankle measured using a goniometer41 42 (see 
supplementary appendix 1), malunion (ankle joint 
incongruity) determined from radiographs (yes or 
no), and fracture union (assessed at 52 weeks). We 
considered fracture union to be complete when the 
fracture line had disappeared, and non-union present 
when the fracture line was visible. Two experienced 
orthopaedic surgeons with no access to clinical data 
or patient reports analysed the radiographs. Except for 
fracture union, we assessed all secondary outcomes 
(FAOS, visual analogue scale, and RAND-36, range of 
motion, ankle joint congruity) at six, 12, and 52 weeks, 
but similarly to OMAS, the data of the interim data 
points were only intended to illustrate the trajectory of 
the treatment responses.
An expert panel consisting of three experienced 
academic orthopaedic trauma surgeons and a 
bilinguist (English and Finnish) translated the OMAS 
and the FAOS questionnaires.
Expected complications or harms related to 
study treatments, which included loss of congruity 
of the ankle joint, venous thromboembolism, 
nerve compression, and fracture non-union, were 
recorded as adverse events. In addition, we recorded 
unexpected adverse events. At each follow-up visit we 
queried about harms, and participants were asked to 
describe any negative effects of the trial treatment. 
The congruity of the ankle joint was confirmed with 
radiography. Two experienced orthopaedic surgeons 
conducted additional ad hoc consultations when 
requested by participants.
Follow-up appointments
Clinical follow-up visits were scheduled at 3, 6, 12, 
and 52 weeks after randomisation at the orthopaedic 
outpatient clinic of the study hospitals. These visits 
included clinical examination and radiography 
(mortise and lateral projections) of the injured ankle 
to assess ankle joint congruity. Immediately before the 
follow-up visits at 6, 12, and 52 weeks, the participants 
independently completed questionnaires assessing 
ankle functional outcome, pain, and quality of life.
Statistical analysis
Sample size calculations were performed assuming a 
two arm study (six week cast versus three week cast 
or versus three week orthotic device). In our previous 
study3 on non-operative treatment of stable ankle 
fractures with the same primary outcome (OMAS), the 
mean OMAS score was 88 (SD 20), and our sample size 
BA C
Fig 1 | Weber classification for lateral malleolar (fibula) 
fractures. Type A: Fracture below level of ankle joint. 
Type B: Fracture starts distally at level of ankle joint 
(syndesmosis) and extends proximally. Type C: Fracture 
proximal to syndesmosis (level of ankle joint)
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calculation was based on this (non-inferiority margin). 
During the design of the present trial, no estimate for 
minimal clinically relevant change existed for OMAS. 
In the absence of better evidence, we organised a 
focus group discussion among experts to define the 
appropriate estimate for non-inferiority margin. The 
panel reached a consensus that a 10% difference in 
0-100 OMAS scale would not be clinically significant, 
which was then used to derive our non-inferiority 
margin (10% equals 8.8 points on the OMAS scale, 
Cohen’s d=0.215, indicating a small effect size). With 
α=0.05, power 80% (1−β=0.8), a non-inferiority 
margin of 10% (8.8 points), and the estimated true 
difference between the novel treatments compared 
with conventional treatment equals 1.0 point in favour 
of the new treatments, with a dropout rate of 20%, the 
calculations resulted in 82 patients in each group (total 
n=246) (see trial protocol, supplementary appendix 
1). Given that some preliminary evidence suggested 
that more functional ankle fracture treatment could 
result in slightly superior outcomes to traditional six 
week treatment with a cast,24 29 we assumed that the 
possible benefit of the three week treatments (cast or 
orthosis) equals one OMAS point.
The trial was primarily designed to ascertain whether 
immobilisation by cast or orthosis for three weeks is 
non-inferior to cast immobilisation for six weeks, 52 
weeks after the injury, with the primary outcome, the 
OMAS. Only the two primary analyses, six week cast 
versus three week cast and six week cast versus three 
week orthosis, were used to assess non-inferiority and 
there was no hierarchy between these two analyses. 
For the primary time point, non-inferiority of the three 
week cast and three week orthosis to six week cast 
could be claimed if the lower limit of the confidence 
interval (for differences in means in OMAS) was greater 
than −8.8 in either of the two primary comparisons. 
According to the CONSORT statement for non-inferiority 
and equivalence trials,35 secondary outcomes can be 
managed using either a superiority or an equivalence 
framework. In our trial, all secondary outcomes were 
assessed with a superiority hypothesis, but as the trial 
was not powered for these comparisons, we merely 
considered them to be hypothesis generating.
Analyses were primarily conducted according to 
the intention-to-treat principle. In the intention-to-
treat analyses, the participants were included as 
randomised. In addition, we carried out per protocol 
analyses to safeguard against the risk of falsely 
claiming non-inferiority.43 Summary statistics are given 
as means (with standard deviations) for continuous 
variables and as frequencies (with percentages) for 
categorical variables. For all continuous variables 
(both primary and secondary outcomes), we used a 
repeated measures mixed model analysis of variance 
with time, group, and time×group as fixed effects and 
patient as a random effect (repeated measurements 
at 6, 12, and 52 weeks) with a two sided 5% level of 
significance. The covariance structure was chosen 
according to Akaike’s Information Criterion, and we 
used the Kenward-Roger method to calculate the 
degrees of freedom.44 As the repeated measures mixed 
model allows the analysis of unbalanced datasets 
without imputation, we analysed all available data; 
the full analysis set. We report the between group 
differences for all continuous outcomes, at 52 weeks, 
with 95% confidence intervals derived from the 
repeated measures mixed model. In addition, we 
provide data from the six week and 12 week trajectory 
time points for the primary outcome. The categorical 
variables—the occurrence of treatment related adverse 
events and non-union—were contrasted with Fisher’s 
exact test and Wilson’s estimate for the confidence 
interval of the absolute risk difference. The statistical 
programs SPSS (2010 release, IBM SPSS Statistics for 
Windows; version 22.0, IBM, Armonk, NY) and SAS 
(version 9.3, SAS Institute, Cary, NC) were used for 
analyses.
Patient and public involvement
No patients were involved in the design process of this 
study, setting the research question, or the outcome 
measures nor were they involved in the analysis, 
interpretation, and writing of the results. Our findings 
from the trial will be shared with all participants, who 
will be provided with a lay abstract of our study and 
access to the full manuscript.
Results
Recruitment took place between 22 December 
2012 and 6 June 2015. Final (52 week) follow-up 
assessments were completed on 6 June 2016. A total 
of 560 patients were assessed for eligibility: 272 were 
eligible and 247 consented to randomisation. Of these 
247 patients, 84 were randomised to the six week cast 
group, 83 to the three week cast group, and 80 to the 
three week orthosis group (fig 2). The main reason for 
exclusion was unstable ankle fracture diagnosed in the 
external rotation test (n=198). Of the 247 participants 
randomised, 244 (99%) were followed-up at three 
weeks, 241 (98%) at six weeks, 221 (89%) at 12 weeks, 
and 212 (86%) at 52 weeks. One patient from the three 
week cast group died for a reason unrelated to ankle 
fracture, about three months from randomisation. 
Table 1 shows the baseline characteristics of the three 
study groups. The average age of participants was 45 
years, and 125 (51%) were men.
Protocol violations occurred only in the six week cast 
group, with six participants declining to continue cast 
treatment beyond the three week clinical appointment. 
Three of these participants consented to wearing a 
removable orthotic device for the subsequent three 
weeks, and the remaining three participants refused 
to use any ankle support. We included these six 
participants in the six week cast group in the intention-
to-treat analysis.
In the primary intention-to-treat analyses, the 
between group difference in the three week cast versus 
six week cast group was 3.6 points (95% confidence 
interval −1.9 to 9.1; P=0.20), and for the three week 
orthosis versus six week cast group was 1.7 points 
(−4.0 to 7.3; P=0.56). These findings are consistent 
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with non-inferiority, as the lower bounds of the two 
sided 95% confidence intervals for the differences 
between means in OMAS did not include the predefined 
non-inferiority margin of —8.8 points (fig 3). At this 52 
weeks follow-up time point, the mean OMAS of the 
three study groups was 87.6 points (SD 18.3) in the 
six week cast group, 91.7 points (SD 12.9) in the three 
week cast group, and 89.8 points (SD 18.4) in the three 
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Fig 2 | Trial profile
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week orthosis group. Per protocol analysis confirmed 
the findings of these intention-to-treat analyses (see 
supplementary appendix 2 table S3).
The only statistically significant between group 
difference in the OMAS was a 7.2 point benefit of the 
three week cast over the six week cast (mean difference, 
95% confidence interval 0.2 to 14.1, P=0.04) at 12 
weeks (fig 4 and supplementary appendix 2, tables S2 
and S3).
Tables S4-S13 of the supplementary appendix 2 
present the data on all secondary outcomes. At the 
primary time point (52 weeks), the only statistically 
significant between group difference in the secondary 
outcomes was a slightly improved ankle plantar 
flexion (mean difference 3.0, 95% confidence interval 
0.2 to 5.8, P=0.04) of those treated with the orthosis 
for three weeks versus those treated with a cast for 
six weeks.
Standard ankle radiographs were missing for 13 
of 84 participants (15%) in the six week cast group, 
11 of 83 (13%) in the three week cast group, and 14 
of 80 (17%) in the orthosis group at 52 weeks. All 
ankle joints remained congruent throughout follow-
up, and accordingly, surgery was not needed in 
any participant to restore a widened ankle mortise. 
However, two cases of non-union were found among 
the participants, both in the three week cast group. 
One of these participants gradually experienced 
symptoms, requiring surgery at 11 months after 
OMAS at 52 weeks
(3 week cast/orthosis minus 6 week cast)









Fig 3 | Presentation and interpretation of primary outcome Olerud-Molander Ankle 
Score (OMAS) at 52 weeks using confidence intervals in relation to non-inferiority 
margin. Given that confidence intervals for both comparisons (three week orthosis 
versus six week cast and three week cast versus six week cast) lie to the right of the 
non-inferiority margin (∆, (−8.8 points)) and also include zero, the interpretation 
is: new treatments (three week orthosis and cast) are non-inferior to the control (six 
week cast) but not shown to be superior. Error bars indicate two sided 95% confidence 
intervals. Dashed line indicates non-inferiority margin; shaded region indicates zone of 
non-inferiority
Table 1 | Baseline characteristic of trial participants. Values are number (percentages) unless stated otherwise
Characteristics 3 week orthosis (n=80) 3 week cast (n=83) 6 week cast (n=84)
Mean (SD) age at fracture (years); range 46 (19); 16-82 46 (17); 16-82 45 (18); 17-85
Patients aged >50 years 36 (45) 37 (45) 33 (41)
Men 36 (45) 43 (52) 46 (45)
Women 44 (55) 40 (48) 38 (45)
Education level:      
 Basic (ISCED 2) 11 (13.8) 11 (13.3) 12 (14.3)
 Upper secondary (ISCED 3 or 4) 31 (38.8) 27 (32.5) 26 (31.0)
 Short cycle tertiary (ISCED 5) 10 (12.5) 16 (19.3) 8 (9.5)
 Bachelor, master's, or doctorate (ISCED 6-8) 22 (27.5) 26 (31.3) 29 (34.5)
 Did not answer or missing 6 (7.5) 3 (3.6) 9 (10.7)
Place of occurrence (ICD-10)*:      
 Leisure activity 66 (82.5) 66 (79.5) 61 (72.6)
 Working for income 5 (6.3) 7 (8.4) 10 (11.9)
 Sports activity 5 (6.3) 4 (4.8) 8 (9.5)
 Other 4 (5.1) 6 (7.2) 5 (6.0)
Mean (SD) pain (NRS)† in ER stress test‡ 5 (3) 4 (3) 4 (2)
Signs of medial injury§:      
 None 44 (55.0) 52 (62.7) 53 (63.1)
 One 11 (13.8) 17 (20.5) 13 (15.5)
 Two 15 (18.8) 10 (12.0) 10 (11.9)
 Three 9 (11.3) 4 (4.8) 8 (9.5)
 Missing 1 (1.3) 0 (0) 0 (0)
Mean (SD) width of medial clear space (mm) in ER stress test¶ 4 (0.5) 4 (0.5) 4 (0.5)
Delay (days) from trauma to enrollment, mean (SD) 1.8 (1.6) 1.6 (1.5) 1.6 (1.6)
ISCED=International Standard Classification of Education. A statistical framework for organising information on education maintained by United Nations 
Educational, Scientific and Cultural Organization (UNESCO); ICD-10=International Statistical Classification of Diseases and Related Health Problems 10th 
revision; NRS=numeric rating scale; ER=external rotation.
*Place of occurrence of external cause according to classification of environmental events and circumstances as cause of injury, poisoning, and other 
adverse effects.
†Scale 0 to 10. Self reported pain scale that measures a patient’s pain intensity, where 0 means no pain, 1-3 mild pain, 4-6 moderate pain, and 7-10 
severe pain.45
‡Performed at emergency department by on-call surgeon to evaluate stability of ankle fracture.11
§Clinical signs of medial injury (yes or no) at emergency department according to McConnell et al.11 Swelling, ecchymosis, and tenderness.
¶Width of medial clear space in external rotation (ER) stress test according to McConnell et al,11 Park et al,12 and Gill et al.13
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injury, whereas the other participant scored 95/100 
on the OMAS at the 52 week follow-up and reported 
no symptoms, and therefore no additional treatment 
was warranted. The overall rate of fracture union 
among the three treatment groups was high (99.2%) 
(see supplementary appendix 2 table S7). No 
significant between group differences were found 
in this outcome, with the 95% confidence intervals 
for fracture non-union ranging from −2.7% to 9.6% 
for the three week cast versus six week cast group 
(P=0.50) and from −5.1% to 5.5% for the three week 
orthosis versus six week cast group (P value not 
calculable).
A symptomatic deep vein thrombosis was diagnosed 
in eight patients (table 2 and supplementary appendix 
2 table S14); five in the six week cast group, three in 
the three week cast group, and none in the orthosis 
group. The between group differences in the incidence 
of deep vein thrombosis (with 95% confidence 
intervals) ranged from −10.0 to 5.0 (P=0.72) for the 
three week cast versus six week cast group and from 
−13.2 to −0.3 (P=0.06) for the three week orthosis 
versus six week cast group. Apart from this latter, 
borderline statistically significant difference, no other 
significant between group differences were observed in 
the incidence of harms (table 2).
Discussion
In adults with a stable Weber B type fibula fracture, 
a strategy of immobilising the injured ankle for 
only three weeks in either a traditional cast or a 
simple orthosis resulted in ankle function and 
fracture healing non-inferior to that of conventional 
immobilisation for six weeks in a cast, without an 
increased risk of complications. As our trial was 
a non-inferiority trial, the rationale was not to 
primarily show that shorter immobilisation results in 
superior effectiveness outcomes, but rather to show 
that outcomes would be sufficiently close to that of 
conventional treatment with no excess harms. If 
proved, it is intuitive that patients would choose the 
shorter or the more convenient treatment strategy. 
Such contention is supported by a recent study from 
the United Kingdom showing that when patients 
with a stable ankle fracture were counselled about 
different options for conservative management and 
then encouraged to make an informed decision 
on which method of treatment they would like to 
pursue, the majority opted not to have a cast.46 In 
this context, no single protocol violation occurred in 
the three week treatment groups, whereas six (7%) 
participants in the six week cast group refused to 
continue the cast treatment beyond the three week 
follow-up appointment.
Comparison with other studies
Our study is not the first attempt to streamline the non-
operative treatment of ankle fractures.24 25 27-30 46-48 
In fact, on the basis of evidence from biomechanical 
studies suggesting that early mechanical stimuli 
can enhance fracture healing,31-33 a few attempts of 
treating isolated fibula fractures without any sturdy 
external ankle support had been carried out.27-29 
However, possibly due to absence of high quality 
evidence on the effectiveness and safety of more 
simple non-operative treatment strategies, the current 
tenet of six weeks of cast immobilisation coupled with 
a series of follow-up radiographs—even weekly48—
still remains the ideal treatment of stable Weber B 
type fractures.8 19 20 22 23 This is based primarily on 
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Fig 4 | Trajectories of treatment responses for primary outcome in three study groups 
over course of trial. Circles represent mean values of each group at each follow-up 
point. Bars indicate standard deviations. OMAS=Olerud-Molander Ankle Score
Table 2 | Treatment related adverse events: complications and harms
Adverse events
No (%) Difference (percentage points) (95% CI)*
6 week cast 3 week cast 3 week orthosis 6 week cast v 3 week cast 6 week v 3 week orthosis
Non-union at 52 weeks 0 2† (2.8) 0 2.8 (−2.7 to 9.6) 0.0 (−5.1 to 5.5)
Loss of congruity of ankle joint‡ 0 0 - 0 - 0.0 (−4.4 to 4.4) 0.0 (−4.4 to 4.6)
Venous thromboembolism (DVT)§ 5 (6.0) 3 (3.6) 0 - −2.3 (−10.0 to 5.0) −6.0 (−13.2 to −0.3)
Complications related to cast or orthosis:
 Nerve compression¶ 1 (1.2) 1 (1.2) 2 (2.5) −1.2 (−6.4 to 3.3) −1.2 (−6.4 to 3.5)
 Plaster/orthosis sore 2 (2.4) – – −1.2 (−7.1 to 4.4) 0.0 (-6.0 to 6.5)
*Wilson method was used for calculating 95% confidence intervals.
†One participant without and one with symptoms who underwent surgery at 11 months after injury.
‡Widening of ankle mortise (incongruity) defined as medial clear space >4 mm and >1 mm wider than superior clear space at mortise view in standard 
radiographs with ankle in neutral dorsiflexion.
§Symptomatic deep vein thrombosis (DVT) diagnosed with colour Doppler ultrasonography.
¶Superficial peroneal nerve compression confirmed or diagnosed with electroneuromyography.
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takes six weeks for any fracture to reach a sufficient 
strength to resist weightbearing induced strains49—
and evidence from clinical trials showing satisfactory 
outcomes in patients with minimally or non-displaced 
Weber B type fibula fractures.16-19 It thus seems that 
although most Weber B type fibula fractures are stable 
and do not require plaster casting to achieve fracture 
union in a good position, orthopaedic surgeons value 
aversion of potential fracture displacement over the 
risks of prolonged immobilisation, including stiffness, 
skin damage, and thromboembolism.
Traditionally, the assessment of the stability of 
the ankle mortise in patients with an isolated fibula 
fracture has relied on plain radiography and consensus 
based indicators for instability: fracture gap more 
than 2 mm, particularly when complemented with 
“red flag” clinical findings on the medial side of the 
ankle (tenderness, swelling, haematoma).16-18 24  27-30 
Occasional cases of treatment failures—widening of the 
ankle mortise—has been associated with this treatment 
strategy.16 18 28 In our trial, we used external rotation 
stress testing, a method gaining popularity,6-9 11-15 to 
confirm the stability of the ankle mortise immediately 
after the injury. Given that not a single loss of congruence 
of the ankle mortise was observed over the course of 
our 52 week follow-up despite allowing participants to 
weightbear as tolerated immediately after injury and 
enrolling more “clinically severe” injury patterns than 
most previous trials16-18 24 27-30 (table 1), the strategy 
proved successful. As the rates of fracture union ranged 
from 97% to 100% in all three groups at the primary 52 
week time point, it seems highly unlikely that a longer 
follow-up time would materially change this finding. 
Consequently, our findings highlight the usefulness 
of implementing external rotation stress testing in the 
initial assessment of patients with ankle fractures and 
they also support the findings of previous studies3 50 51 
questioning the need for repetitive, routine radiography 
in the follow-up of these fractures once the stability of 
the ankle mortise has been confirmed initially.
Strengths and limitations of this study
The appropriateness of the chosen non-inferiority 
margin is a critical methodological issue regarding 
the validity of any non-inferiority trial.35 Although 
no valid evidence existed on this problem while we 
were designing our trial, a recent study reported that 
the smallest real difference for the OMAS score is 12 
points,37 which is clearly higher than the 8.8 point we 
set as our non-inferiority margin. Our follow-up rates 
(>95% at three and six weeks and >85% at 12 and 52 
weeks) proved similar to the follow-up rates reported 
in two recent high quality trials on the management 
of ankle fractures.26 52 We believe the results of this 
trial are generalisable to most patients with isolated, 
stable Weber B type ankle fractures, as both study 
hospitals were virtually the only hospitals treating 
ankle fractures within each catchment area.
Some limitations warrant discussion. One can 
question the chosen study design of using the six week 
cast group as a comparator for both the three week cast 
and the three week orthosis groups without correcting 
for multiple testing. Controversy exists about the 
necessity of multiplicity correction, particularly with 
respect to non-inferiority trials53 54—as also reflected by 
considerable variation in contemporary practices.54 We 
deemed that no correction for multiplicity (adjustment 
of significance) was necessary.
In retrospect, it would have been more optimal 
to choose secondary outcomes that are clearly 
complementary to our primary outcome, assessing 
qualities that the new treatment is expected to offer 
benefits on, such as lower cost or greater ease of 
use. However, we believed that the advantages the 
new treatments offer are so obvious (cutting the 
immobilisation period to half) that they justify the new 
treatments if non-inferiority was proved. It can also 
be argued that owing to the non-inferiority design, 
protocol violations in the six week cast treatment 
group (n=6) skew our intention-to-treat analyses. 
However, the findings of the intention-to-treat analyses 
were confirmed in the per protocol analyses (see 
supplementary appendix 2, tables S3 and S9-13).
Owing to an error made in calculating the 
sample size, we recruited approximately 25% more 
participants than would have been required (see 
supplementary appendix 2). It might seem paradoxical 
that in a non-inferiority setting we assumed the new 
(three week) treatments to be slightly more effective 
than the conventional control. However, this decision 
was based on the results of previous randomised 
controlled trials24 29 indicating that more functional 
treatment of ankle fractures could be superior to 
traditional immobilisation by cast for six weeks. In our 
sample size calculation, we cautiously estimated the 
“improvement” to equal 1 OMAS point—an estimate 
that proved quite accurate. This approach also has 
been advocated as being more patient friendly (fewer 
participants randomised to the placebo or control arm) 
and consequently, having also the benefit of reducing 
the required sample size.55
The generalisability of our findings might be 
questioned, as external rotation stress testing is not 
universally used to confirm the ankle mortise stability. 
Although true, we feel that our findings make a 
strong case for wider adoption of external rotation 
stress testing in this setting. Similarly, the two cases 
of fracture non-union might raise concerns that the 
three week immobilisation does not provide sufficient 
stability or allows harmful micromotion within the 
fracture line. However, both non-unions took place 
in the three week cast group rather than in the less 
rigid orthosis group. Moreover, if the non-unions 
were indeed attributable to instability, they should 
have been hypertrophic, but they were atrophic. This 
finding rather suggests lack of biology or vascularity 
as the root cause. Given the low overall incidence of 
non-unions and their counterintuitive occurrence in 
the more rigid of the two three week immobilisation 
groups, we are inclined to think that the two cases 
represent a random phenomenon rather than being 
attributable to inadequate immobilisation.
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Finally, an argument can be made that all fracture 
trials should systematically document potential risk 
factors for complications with fracture healing (eg, 
body mass index, diabetes, tobacco consumption, 
and use of non-steroidal anti-inflammatory drugs). 
However, although factors such tobacco consumption, 
body mass index, and alcohol intake might affect how 
patients are treated by hospital staff, selection and 
confounding bias represent systematic differences 
that are prevented by successful randomisation and 
concealed allocation because all differences between 
the randomised groups must then be random. Although 
our three treatment groups showed no noticeable 
differences in baseline characteristics (table  1), we 
also carried out adjusted analyses to test that our 
results were not confounded by any residual baseline 
imbalances (see supplementary appendix 2, tables 
S15 A-F). The results of these sensitivity analyses were 
similar to the unadjusted analyses.
The use of a functional orthosis has been associated 
with a reduced incidence of symptomatic deep vein 
thrombosis compared with cast treatment in patients 
with ankle fractures,24 56 57 prompting assertions that 
more functional or shorter periods of immobilisation 
could have a preventive effect on thromboembolic 
complications in these patients.23 24 Our findings of 
reduced incidence of deep vein thromboses (table 2) 
could be interpreted as supportive of such hypothesis. 
However, all these studies, including our trial, lack the 
required power for definite conclusions. Considering 
the reported incidence of symptomatic venous 
thromboembolism in patients with fractures below the 
knee in recent high quality studies (0.6% to 1.9%),58-60 a 
trial of between 600 to 1000 patients would be needed to 
definitely address the potential effect of any intervention 
on incidence of deep vein thrombosis or pulmonary 
embolism in this context.
Conclusions and policy implications
A shorter, three week period of immobilisation, either 
by cast or a simple orthosis, proved non-inferior to 
traditional six weeks of cast immobilisation for patients 
with stable, isolated Weber B type fibula fractures.
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